BTIG Cuts Organogenesis Confidence on CMS Policy Delay
BTIG maintains $9 price target on Organogenesis but reduces 2026 confidence after CMS delays skin substitute coverage rules, creating regulatory uncertainty for the wound care company.
/ 3 items
#ORGO↓
ReNu Knee Treatment Moves Forward with FDA Approval Process
Organogenesis receives FDA clearance to file for approval of ReNu, a regenerative treatment for knee osteoarthritis pain affecting millions of Americans.
Organogenesis Trial Failure Sinks Stock Price
ReNu's second trial for knee pain (OA) missed its main goal, but still showed numerical improvement and function benefits. Organogenesis, confident in the data from all three large studies (1,300+ patients), will ask the FDA to review combined results for approval.